ArticleJournal of gastroenterology and hepatology2026
Prospective Clinical Evaluation of a Novel Repositionable Plastic Stent for Endosonography-Guided Hepaticogastrostomy With or Without Antegrade Stenting (With Videos).
Article in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND STUDY
aimsA repositionable plastic stent (PS), developed to overcome the limitations of conventional pusher-type PS in endosonography-guided hepaticogastrostomy (EUS-HGS), minimizes the gap between the inner sheath and stent to improve insertability. This prospective single-center study evaluated its feasibility, safety, and clinical effectiveness in malignant and benign biliary diseases. PATIENTS AND
methodsBetween August 2022 and August 2024, 100 consecutive patients undergoing EUS-HGS using the repositionable PS were enrolled. Mechanical tract dilation was performed, and antegrade metal stenting was added when feasible.
resultsTrainees performed 76% of the procedures. The median bile duct diameter was 4.3 mm. Technical and functional success rates were 99% and 93.9%, respectively, without need for cautery dilation. Initial PS advancement failed in two benign cases with rigid bile ducts; the stent system was pulled back for additional dilation, enabling successful placement. Adverse events occurred in 10% of cases (biliary peritonitis, 6; cholangitis, 2; biloma from early stent bending, 1; bleeding, 1), all manageable, with intervention required in two cases. No stent migration occurred during the first month after insertion. Recurrent biliary obstruction developed in 24 cases, all with successful reintervention. Median time to recurrence of biliary obstruction was significantly longer for EUS-HGS combined with antegrade stenting than for EUS-HGS alone (389 vs. 168 days, p < 0.001).
conclusionsThis repositionable PS enables safe, effective EUS-HGS using mechanical dilation alone and corrective pullback for difficult cases. Its controlled deployment and reliable reintervention support its usefulness in both malignant and benign biliary diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.